BR0116151A - Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica - Google Patents

Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica

Info

Publication number
BR0116151A
BR0116151A BR0116151-2A BR0116151A BR0116151A BR 0116151 A BR0116151 A BR 0116151A BR 0116151 A BR0116151 A BR 0116151A BR 0116151 A BR0116151 A BR 0116151A
Authority
BR
Brazil
Prior art keywords
induced
factor vii
bleeds
coagulation factor
activated coagulation
Prior art date
Application number
BR0116151-2A
Other languages
English (en)
Inventor
Cord Skamira
Jean Marie Stassen
Gerhard Heusel
Wolfgang Wienen
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0116151A publication Critical patent/BR0116151A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"USO DE FATOR DE COAGULAçãO ATIVADA VII PARA TRATAMENTO DE SANGRAMENTOS PRINCIPAIS INDUZIDOS NA TERAPIA TROMBOLìTICA". A invenção refere-se a grandes sangramentos induzidos por terapia trombolítica/fibrinolítica, incluindo hemorragias intracraniais que são tratadas, administrando ao indivíduo sofrendo de tais sangramentos, uma quantidade eficaz de fator VII (VIIa) ativado de coagulação ou um derivado funcional do mesmo.
BR0116151-2A 2000-12-21 2001-12-20 Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica BR0116151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128252A EP1216709A1 (en) 2000-12-21 2000-12-21 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings
PCT/EP2001/015132 WO2002049665A2 (en) 2000-12-21 2001-12-20 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings

Publications (1)

Publication Number Publication Date
BR0116151A true BR0116151A (pt) 2003-10-21

Family

ID=8170769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116151-2A BR0116151A (pt) 2000-12-21 2001-12-20 Uso de fator de coagulação ativada vii para tratamento de sangramentos principais induzidos na terapia trombolìtica

Country Status (25)

Country Link
US (2) US20040087502A1 (pt)
EP (2) EP1216709A1 (pt)
JP (1) JP2004516273A (pt)
KR (1) KR20030063454A (pt)
CN (1) CN1482919A (pt)
AT (1) ATE353666T1 (pt)
AU (2) AU2638602A (pt)
BR (1) BR0116151A (pt)
CA (1) CA2431986A1 (pt)
CY (1) CY1106363T1 (pt)
CZ (1) CZ300670B6 (pt)
DE (1) DE60126650T2 (pt)
DK (1) DK1343523T3 (pt)
EC (1) ECSP034647A (pt)
ES (1) ES2280429T3 (pt)
HU (1) HUP0302574A3 (pt)
IL (1) IL155886A0 (pt)
MX (1) MXPA03005641A (pt)
NZ (1) NZ549850A (pt)
PL (1) PL205878B1 (pt)
PT (1) PT1343523E (pt)
RU (1) RU2286796C2 (pt)
SI (1) SI1343523T1 (pt)
WO (1) WO2002049665A2 (pt)
ZA (1) ZA200304140B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
RU2396086C2 (ru) * 2004-09-10 2010-08-10 Фармаоригин Апс Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
EP1906993A2 (en) * 2005-07-15 2008-04-09 Novo Nordisk Health Care AG USE OF FACTOR VIIa OR FACTOR VIIa EQUIVALENTS FOR PREVENTING OR ATTENUATING HAEMORRHAGE GROWTH, AND/OR OEDEMA GENERATION FOLLOWING INTRACEREBRAL HAEMORRHAGE (ICH) IN PATIENTS TREATED WITH ANTIPLATELET THERAPY
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
RU2552339C1 (ru) * 2014-02-19 2015-06-10 Общество с ограниченной ответственностью фирма "Технология-Стандарт" Способ профилактики кровотечений, вызванных применением стрептокиназы, в эксперименте

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382082A (en) * 1980-12-18 1983-05-03 Uop Inc. Recovery of cobalt values by absorption from ammoniacal solution
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function

Also Published As

Publication number Publication date
HUP0302574A2 (hu) 2003-10-28
RU2286796C2 (ru) 2006-11-10
NZ549850A (en) 2008-04-30
CA2431986A1 (en) 2002-06-27
PT1343523E (pt) 2007-03-30
EP1343523A2 (en) 2003-09-17
HUP0302574A3 (en) 2010-01-28
US20040087502A1 (en) 2004-05-06
DE60126650T2 (de) 2007-10-31
KR20030063454A (ko) 2003-07-28
MXPA03005641A (es) 2004-12-03
IL155886A0 (en) 2003-12-23
EP1343523B1 (en) 2007-02-14
ECSP034647A (es) 2003-07-25
WO2002049665A2 (en) 2002-06-27
EP1216709A1 (en) 2002-06-26
PL361855A1 (en) 2004-10-04
DE60126650D1 (de) 2007-03-29
SI1343523T1 (sl) 2007-04-30
DK1343523T3 (da) 2007-04-10
US20080286259A1 (en) 2008-11-20
WO2002049665A3 (en) 2002-09-26
PL205878B1 (pl) 2010-06-30
AU2638602A (en) 2002-07-01
CY1106363T1 (el) 2011-10-12
AU2002226386B2 (en) 2005-12-22
JP2004516273A (ja) 2004-06-03
CN1482919A (zh) 2004-03-17
ES2280429T3 (es) 2007-09-16
ATE353666T1 (de) 2007-03-15
ZA200304140B (en) 2004-04-22
CZ20031743A3 (cs) 2003-11-12
CZ300670B6 (cs) 2009-07-15
RU2003122362A (ru) 2005-02-10

Similar Documents

Publication Publication Date Title
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
PT816376E (pt) Inibidores de trombina como agentes anticoagulantes
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
ATE507839T1 (de) Kombinationstherapie
PT1259512E (pt) Compostos de pteridin para o tratamento da psoriase
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE60035870D1 (de) Kombinationstherapie zur gewichtsreduzierung und fettleibigkeitsbehandlung
BR0316502A (pt) Compostos quìmicos
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0211450A (pt) Método terapêutico
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0117009A (pt) Composiçoes para utilização no tratamento de distúrbios associados a ige
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0211635B8 (pt) composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]